Cytokine Delivery and Tissue Engineering

Yonsei Medical Journal

Volumn 41, Issue 6, 2000, Pages 704-719

  Lee, Seung Jin ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Cytokines; Peptide delivery; Vehicle

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYTOKINE; GROWTH PROMOTOR;

ANIMAL; BIOMEDICAL ENGINEERING; METHODOLOGY; REVIEW;

ANIMALS; BIOMEDICAL ENGINEERING; BONE MORPHOGENETIC PROTEINS; CYTOKINES; GROWTH SUBSTANCES;

EID: 0034564242     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2000.41.6.704     Document Type: Review

References (169)

1. Putnam AJ, Mooney DJ. Tissue engineering using synthetic extracellular matrices. Nature Med 1996;2:824-6.
2. Skalak R, Fox CF. Tissue engineering. Ann Biomed Eng 1991;19:529-40.
3. Pomahac B, Svensjo T, Yao F, Brown H, Ericksson E. Tissue engineering of skin. Crit Rev Oral Biol Med 1998;9:333-44.
4. Freed LE, Vunjaknovakovic G, Langer R. Cultivation of cell-polymer cartilage implants in bioreactors. J Cell Biochem 1993;51:257-64.
5. Crane GM, Ishaug SL, Mikos AG. Tissue engineering of bone. Nature Med 1995;1:1322-4.
6. Nimni ME. Polypeptide growth factors: Targeted delivery systems. Biomaterials 1997;18:1201-25.
7. McKay IA, Leigh I. In Growth factors: A Practical Approach. Oxford: IRL press; 1993.
8. Ahrendt G, Chickering DE, Ranieri JP. Angiogenic growth factors; A review for tissue engineering. Tissue Engineering 1998;4:117-30.
9. Schmitt JM, Hwang K, Winn SR, Hollinger JO. Bon morphogenetic proteins: An update on basic biology and clinical relevance. J Orthop Res 1999;17:269-78.
10. Parker TG, Schneider MD. Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Annu Rev Physiol 1991;53:179-200.
11. Florini JR, Ewton DZ, Magri KA. Hormones, growth factors, and myogenic differentiation. Annu Rev Physiol 1991;53:201-16.
12. Canalis E, McCarthy TL, Centrell M. Growth factors and cytokines in bone metabolism. Annu Rev Med 1991;42: 17-24.
13. Bowen-Pope DF, Malpass TW, Foster DM, Ross R. Platelet-derived growth factor in vivo: levels, activity, and rate of clearance. Blood 1984;64:458-69.
14. Lo H, Kadiyala S, Guggino SE, Leong KW. Poly (L-lactic acid) foams with cell seeding and controlled-release capacity. J Biomed Mater Res 1996;30:475-84.
15. Whang K, Tsai DC, Nam EK, Aitken M, Sprague SM, Patel PK, et al. Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mater Res 1998;42:491-9.
16. Fournier N, Doillon CJ. Biological molecule-impregnated polyester: An in vivo angiogenesis study. Biomaterials 1996;17:1659-65.
17. Tabata Y, Nagano A, Ikada Y. Biodegradation of hydrogel carrier incorporating fibroblast growth factor. Tissue Engineering 1999;5:127-38.
18. Schoichet MS, Gentile FT, Winn SR. The use of polymers in the treatment of neurological disorders. A discussion emphasizing encapsulated cell therapy. TRIP 1995;3:374-80.
19. Babensee JE, McIntire LV, Mikos AG. Growth factor delivery for tissue engineering. Pharm Res 2000;17:497-504.
20. Murphy WL, Mooney DJ. Controlled delivery of inductive proteins, plasmid DNA and cells from tissue engineering matrices. J Periodont Res 1999;34:413-9.
21. Urist MR. Bone:formation by autoinduction. Science 1965;150:893-9.
22. Urist MR, Richard C, Cameron C. Collagen and a Thermally Reversible Poloxamer to Deliver Demineralized Bone Mikulski A, Lietze A. Solubilized and insolubilized bone morphogenetic protein. Proc Natl Acad Sci USA 1979;76:1828-32.
23. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-34.
24. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992;32:160.
25. Reddi AH. Morphogenesis and tissue engineering of bone; inductive signals, stem cells and biomimetic biomaterials. Portland Bone Symposium 1999;121-36.
26. Cook SD, Baffes GC, Wolfe MW, Sampath TK, Rueger DC, Whitecloud TS. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am 1994;76:827-38.
27. Cook SD, Baffes GC, Wolfe MW, Sampath TK, Rueger DC. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop 1994;301:302-12.
28. Cook SD, Wolfe MW, Salkeld SL, Rueger DC. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am 1995;77:734-50.
29. Riley EH, Lane JM, Urist MR, Lyons KM, Lieberman JR. Bone morphogenetic protein-2. Biology and Applications 1996;324:39.
30. Rosen V, Thies RS. The BMP proteins in bone formation and repair. Trends 1992;8:7.
31. Yasko AW, Lane JM, Fellinger EJ, Rosen V, Wozney JM, Wang EA. The healing of segmental bone defects induced by recombinant human bone morphogenetic protein (rhBMP-2): A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg 1992; 74-A:659.
32. Wang EA, Rosen VD, D'Alessandro JS, Bauduy M, Cordes P, Harada T, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990;87:2220-4.
33. Gitelman S, Kobrin M, Ye J, Lopez A, Lee A, Derynck R. Recombinant Vgr-/BMP-6-expressing tumors induce fibrosis and endochrondral bone formation in vivo. J Cell Biol 1994;126:1595-609.
34. Shimizu K, Yoshikawa H, Takaoka K. Local effects of bone morphogenetic protein-4 on skeletal tissues. Clin Orthop 1995;318:243-50.
35. Gerhart TN, Kirker-Head CA, Kriz MJ, Holtrop ME, Hennig GE, Hipp J, et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop 1993;293:317-26.
36. Linde A, Hedner E. Recombinant bone morphogenetic protein-2 enhances bone healing, guided by osteopromotive e-PTFE membranes: an experimental study in rats. Calcif Tissue Int 1995;56:549-53.
37. Toriumi DM, Kotler HS, Luxenberg DH, Holtrop ME, Wang EA. Mandibular reconstruction with a recombinant bone-inducing factor. Functional, histologic, and biomechanical eveluation. Arch Otolaryngol Head Neck Surg 1991;117:1101-12.
38. Klein-Nulend J, Semeins CM, Mulder JW, Winters HA, Goei SW, Ooms ME, et al. Stimulation of cartilage differentiation by osteogenic protein-1 in cultures of human perichondrium. Tissue Engineering 1998;4:305-13.
39. Seller RS, Peluso D, Morris EA. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. J Bone Joint Surg Am 1997;79:1452-63.
40. Rodeo SA, Suzuki K, Deng XH, Wozney J, Warren RF. Use of recombinant human morphogenetic protein-2 to enhance tendon healing in a bone tunnel. Am J Sports Med 1999;27:476-88.
41. Richard C, Cameron C, Sean P. Collagen and a thermally reversible poloxamer to deliver demineralized bone matrix (DBM) and Biologically Active Progeins to Sites of Bone Regeneration. Portland Bone Symposium 1999; 619-37.
42. Urist MR. Experimental delivery system for bone morphogenetic protein. In: Wise DL, editor. Encyclopedic Handbook of Biomaterials and Bioengineering-Materials and Applications. New York: Marcel Dekker, Inc; 1995. 1(A):1093.
43. Boyn BD, Lohmann CH, Somers A, Niederauer GG, Wozney JM, Dean DD, et al. Potential of porous poly-D, L-lactide-co-glycolide prticles as a carrier for recombinant human bone morphogenetic protein-2 during osteoinduction in vivo. J Biomed Mater Res 1999;46: 51-9.
44. Isobe M, Yamazake Y, Mori M, Amagasa T. Bone regeneration produced in rat femur defects by polymer capsules containing recombinant human bone morphogenetic protein-2. J Oral Maxillofac Surg 1999;57:695-8.
45. Mori M, Yamazaki Y, Ishihara K, Nakabayashi N. Restoration of segmental bone defects in rabbit radius by biodegradable capsules containing recombinant human bone morphogenetic protein-2. J Biomed Mater Res 2000;50:191-8.
46. Rodgers JB, Vasconez HC, Wells MD, DeLuca PP, Faugere MC, Fink BF, et al. Two lyophilized polymer matrix recombinant human bone morphogenetic protein-2 carriers in rabbit calvarial defects. J Craniofac Surg 1998;9: 147-53.
47. Zellin G, Linde A. Importande of delivery systems for growth-stimulatory factors in combination with osteopromotive membranes. An experimental study using rhBMP-2 in rat mandibular defects. J Biomed Mater Res 1997;35:181-90.
48. Miki T, Harada K, Imai Y, Enomoto S. Effect of freeze-dried poly-L-lactic acid discs mixed with bone morphogenetic protein on the healing of rat skull defects. J Oral Maxillofac Surg 1994;52:387-91.
49. Miyamoto S, Takaoka K. Bone induction and bone repair by composites of bone repair by composites of bone morphogenetic protein and biodegradable synthetic polymers. Ann Chir Gynaecol Suppl 1993;207:69-75.
50. Mattioli-Belmonte M, Gigante A, Muzzarelli RA, Politano R, De Benekittis A, Specchia N, et al. N,N-dicarboxyl chitosan as delivery agent for bone morphogenetic protein in the repair of articular cartilage. Med Biol Eng Comput 1999;37:130-4.
51. Harden LJ, Hollinger JO, Chaudhari A, Turek T, Schaub RG, Ron E. Recombinant human bone morphogenetic protein-2 is superior to demineralized bone matrix in repairing craniotomy defects in rats. J Biomed Mater Res 1994;28:1127-38.
52. Urist MR, Nilsson O, Rasmussen J, Hirota W, Lovell T, Schmalzreid T, et al. Bone regeneration under the influence of a bone morphogenetic protein (BMP) beta tricalcium phosphate (TCP) composite I skull trephine defects in dogs. Clin Orthop 1987;214:295-304.
53. Ohuta K, Hamanish C, Tanaka S, Matsuda N. Healing of segmental bone defects in rats induced by a beta-TCP-MCPM cement combined with rhBMP-2. J Biomed Mater Res 1999;44:168-75.
54. Clokie CM, Urist MR. Bone morphogenetic protein excipients: comparative observations on poloxamer. Plast Reconstr Surg 2000;105:628-37.
55. Dibiase MD, Rhodes CT. The design of analytical methods for use in topical epidermal growth factor product development. J Pharm Pharmacol 1991;43:553-8.
56. Jyung RW, Mustoe TA. Role of cytokines in wound repair. In: Oppenhiem JJ, Rossio JL, Gearing AJH, editors. Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis, and Therapy. Oxford: Oxford University Press; 1992. p.307-28.
57. Brown LG, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curtsinger LT 3rd, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989;321:76-9.
58. Brown GL, Curtsinger LJ, White M, Mitchell RO, Pietsch J, Nordquist R, et al. Acceleration of tensile strength of incisions treated with EGF and TGF-β. Ann Surg 1988;208:788-94.
59. Tripathi RC, Raja SC, Tripathi BJ. Prospects for epidermal growth factor in the management of corneal disorders. Surv Ophthalmol 1990;34:457-62.
60. Schuitz G, Rotatori DS, Clark W. EGF and TGF-alpha in wound healing and repair. J Cell Biochem 1991;45: 346-52.
61. Von Recum H, Kikuchi A, Yamato M, Sakurai Y, Okano T, Kim SW. Growth factor and matrix molecules preserve cell function on thermally responsive culture surfaces. Tissue Engineering 1999:5:251-65.
62. Sheardown H, Clark H, Wedge C, Apel R, Rootman D, Cheng YL. A semi-solid drug delivery system for epidermal growth factor in corneal epithelial wound healing. Curr Eye Res 1997;16:183-90.
63. Menetrey J, Kasemkijwattana C, Day CS, Bosch P, Fu FH, Moreland MS, et al. Direct-, fibroblast- and myoblast-mediated gene transfer to the anterior cruciate ligament. Tissue Engineering 1999;5:435-42.
64. Rosenthal FM, Cao L, Tanczos E, Kopp J, Andree C, Stark GB, et al. Paracrine stimulation of keratinocytes in vitro and continuous delivery of epidermal growth factor to wounds in vivo by genetically modified fibroblasts transfected with a novel chimeric construct. In Vivo 1997;11:201-8.
65. Wang JS. Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants. Acta Orthop Scand Suppl 1996;269:1-33.
66. Baird A, Walicke P. Fibroblast growth factors. Br Med Bull 1989;45:438-52.
67. Edelman ER, Mathiowitz E, Langer R, Klagsbrun M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 1991;12:619-26.
68. DeBlois C, Cote MF, Doilon CJ. Heparin-fibroblasst growth factor-fibrin complex: in vitro and in vivo application to collagen-based materials. Biomaterials 1994; 15:665-72.
69. Rosenblum SF, Frenkel S, Ricci JR, Alexander H. Diffusion of fibroblast growth factor from plaster of Paris carrier. J Appl Biomater 1993 spring;4:67-72.
70. Pandit AS, Wilson DJ, Feldman DS. Firbrin scaffold as an effective vehicle for the delivery of acidic fibroblast growth factor (FGF-1). J Biomater Appl 2000 Jan;14: 229-42.
71. Wissink MJB, Beernink R, Poot AA, Engbers GHM, Beugeling T, van Aken WG, et al. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release 2000;64:103-14.
72. Baird A. Potential mechanisms regulating the extracellular activities of basic fibroblast growth factor (FGF-2). Mol Reprod Dev 1994;39:43-8.
73. Tabata Y, Hijikata S, Muniruzzaman M, Ikada Y. Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sei Polym Ed 1999;10:79-94.
74. Tabata Y, Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 1999;20:2169-75.
75. Laham RJ, Rezaee M, Post M, Novicki D, Sellke FW, Pearlman JD, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000;292:795-802.
76. Watanabe E, Smith DM, Sun J, Smart FW, Delcarpio JB, Roberts TB, et al. Effect of basic fibroblast growth on angiogenesis in the infarted porcine heart. Basic Res Cardiol 1998;93:30-7.
77. Hom DB, Winsters M. Effects of angiogenic growth factors and a penetrance enhancer on composite grafts. Ann Otol Rhinol Laryngol 1998;107(9 pt 1):769-74.
78. Tabata Y, Miyao M, Inamoto T, Ishii T, Hirano Y, Yamaoki Y, et al. De novo formation of adipose tissue by controlled release of basic fibroblast growth factor. Tissue Engineering 2000;6:279-89.
79. Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi S, et al. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 1993;9:73-80.
80. Nagi H, Tsukuda R, Mayahara M. Effect of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 1995;16:367-73.
81. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, et al. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 1995;136: 1276-84.
82. Kawaguchi H, Kurokawa T, Hanada K, Hiyama Y, Tamura M, Ogata E, et al. Stimulation of fracture repair by recombinant human basic fibroblast growth factor in mormal and streptozotocin-diabetic rats. Endocrinology 1994;135:774-81.
83. Inui K, Maeda H, Sano A, Fujioka K, Yatani Y, Sakawa A, et al. Local application of basic fibroblast growth factor minipellet induces the healing of segmental bony degects in rabbits. Calcif Tissue Int 1998;63:490-5.
84. Aspenberg P, Lohmander LS. Fibroblast growth factor stimulates bone formation. Bone induction studied in rats. Acta Orthop Scand 1989;60:473-6.
85. Aspenberg P, Thorngren KG, Lohmander LS. Dose-dependent stimulation of bone induction by basic fibroblast growth factor in rats. Acta Orthop Scand 1991;62: 481-4.
86. Zellin G, Linde A. Effects of Recombinant human fibroblast growth factor-2 on osteogenic cell populations during orthopic osteogenesis in vivo. Bone 2000;26: 161-8.
87. Kimoto T, Hosokawa R, Kubo T, Maeda M, Sano A, Akagawa Y. Continuous administration of basic fibroblast growth factor (FGF-2) accelerates bone induction on rat calvaria-an application of a new drug delivery system. J Dent Res 1998;77:1965-9.
88. Shelly ES, Jeffery AH. Development of fibrin derivates for controlled release of heparin-binding growth factors. J Control Release 2000;65:389-402.
89. Kanada T, Iwasaki T, Nakamura S, Kurokawa T, Ikeda K, Mizusawa H. Self-secreation of fibroblast growth factor-9 supports basal forebrain cholinergic neurons in an autocrine/paracrine manner. Brain Res 2000;876:22-30.
90. Terenghi G. Peripheral nerve regeneration and neurotrophic factors. J Anat 1999;194(Pt 1):1-14.
91. Meyer M, Rasmussen JZ. Neuronal growth factors-neurotrophins. Ugeskr Laeger 1999;161:2063-70.
92. Bax B, Blundell TL, Murray-Rust J, McDonald NQ. Structure of mouse 7S NGF: a complex of nerve growth factor with four binding proteins. Structure 1997;5: 1275-85.
93. Hadlock T, Sundback C, Koka R, Hunter D, Cheny M, Vacanti J. A novel, biodegradable polymer conduit delivers neurotrophins and promotes nerve regeneration. Laryngoscope 1999;109:1412-6.
94. Li XB, Liao GS, Shu YY, Tang SX. Brain delivery of biotinylated NGF bounded to an avidinOtransferrin conjugate. J Nat Toxins 2000;9:73-83.
95. Mohammad JA, Warnke PH, Pan YC, Shenaq S. Increased axonal regeneration through a biodegradable amnionic tube nerve conduit: effect of local delivery and incorporation of nerve growth factor/hyaluronic acid media. Ann Plast Surg 2000;44:59-64.
96. Yu X, Dillon GP, Bellamkonda RB. A laminin and nerve growth factor-laden three-dimensional scaffold for enhanced neurite extension. Tissue Engineering 1999;5: 291-304.
97. Menei P, Pean JM, Nerriere-Daguin V, Jollivet C, Brachet P, Benoit JP. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp Neurol 2000;161: 259-72.
98. Balk SD, Whitfield JF, Youdale T, Brown AC. Roles of calcium, serum, plasma and folic acid in the control of proliferation of normal and rous sarcoma-virus infected chicken fibroblasts. Proc Natl Acad Sci USA 1973;70: 675-9.
99. Deuel TF. Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol 1987; 3:443-92.
100. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155-69.
101. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-78.
102. Huang JS, Huang SS, Deuel TF. Specific covalent binding of platelet-derived growth factor to human plasma α2-macroglobulin. Proc Natl Acad Sci USA 1984;81: 343-6.
103. Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science 1989;243:1564-70.
104. Bowen-Pope DF, Malpass TW, Foster DM, Ross R. Platelet-derived growth factor in vivo: levels, activity, and rate of clearance. Blood 1984;64:458-69.
105. Winkles JA, Gay CG. Regulated expression of PDGF A-chain mRNA in human saphenous vein smooth muscle cells. Biochem Biophys Res Commun 1991;180:519-24.
106. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME. Growth factor messenger RNA expression by human breast fibroblasts from genign and malignant lesions. Cancer Res 1991;51:4978-85.
107. Collins T, Ginsburg D, Boss JM, Orkin SH, Pober JS. Cultured human endothelial cells express platelet-derived growth factor B chains: cDNA cloning and structural analysis. Nature (London) 1985;316:748-50.
108. Collins T, Pober JS, Gimbrone MA, Hammacher A, Betshots C, Westermark B, et al. Dultured human endothelial cells express platelet-derived growth factor A chain. Am J Pathol 1987;127:7-12.
109. Morgan CJ, Pledger WJ. In Fibroblast Proliferation in Wound Healing: Biochemical and Clinical Aspects. In: Cohen JK, Diegelmann RF, Lindblad WJ, editors. Philadelphia: Saunders WB; 1992. p.63-76.
110. Blatti SP, Foster DN, Ranganathan G, Moses HL, Getz MJ. Induction of fibronectin gene transcription and mRNA is a primary response to growth factor stimulation of AKR-2B cells. Proc Natl Acad Sei USA 1988; 85:1119-23.
111. Heldin P, Laurent TC, Heldin CH. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. J Biochem 1989;258:919-22.
112. Giannobile WV. Periodontal tissue engineering by growth factors. Bone 1996;19:23-7.
113. Matsuda N, lin WL, Kumar NM, Cho MI, Genco RJ. Mitogenic, chemotactic and synthetic responses of rat periodontal ligament fibroblastic cells to polypeptide growth factors in vitro. J Periodontol 1992;63:515-25.
114. Cho ML, Lin WL, Genco RJ. Platelet-derived growth factor-modulated guided tissue regenerative therapy. J Periodontol 1995;66:522-30.
115. Lynch SE, Castilla GR, Williams RC, Kiritsy CP, Howell TH, Reddy MS, et al. The effects of short-term application of a combination of platelet-derived and insulin-like growth factors on periodontal wound healing. J Periodontol 1991;62:458-67.
116. Giannobile WV, Whitson SW, Lynch SE. Synergistic effects of insulin-like growth factor-I (IGF-I) with other growth factors on bone formation in vitro. J Dent Res 1994;73:205-10.
117. McGill JJ, Strates BS, McGuire MH. Stimulation of osteogenesis by PDGF and TGF adsorbed on microcrystals of hydroxyapatite. J Bone Miner Res 1991;6:503.
118. Selvig KA, Wikesjo UME, Bogle BC, Finkelmann RD. Impaired bone formation in periodontal fenestration defects in dogs following application of insulin-like growth factor (II). Basic fibroblasts growth factor and transforming growth factor beta I. J Clin Periodontol 1994;21:380-5.
119. Beck LS, Deguzman L, Lee WO, Xu Y, McFatridge LA, Gillett NA, et al. TGF-beta I induces bone closure of skull defects. J Bone Miner Res 1991;6:1257-65.
120. Park JB, Matsumura M, Han KY, Norderyd O, Lin WL, Genco RJ, et al. Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. J Periodontol 1995;66:462-77.
121. Rutherford RB, Niekrash CE, Kennedy JE, Charette MF. Platelet-derived and insulin-like growth factors stimulate regeneration of periodontal attachment in monkeys. J Periodontal Res 1992;27:285-90.
122. Lynch SE, Williams RC, Poison AM, Howel Th, Reddy MS, Zappa UE, et al. A combination of platelet-derived and insulin like growth factors enhances periodontal regeneration. J Periodontol 1989;16:545-8.
123. Park YJ, Lee YM, Lee JY, Seol YJ, Chung CP, Lee SJ. Controlled release of platelte-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration. J Control Release. 2000;67:385-94.
124. Jiang D, Dziak R, Lynch SE, Stephan EB. Modification of an osteoconductive anorganic bovine bone mineral matrix with growth factors. J Periodontol 1999;70:834-9.
125. Lind M. Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. Acta Orthop Scand Suppl 1998;283:2-37.
126. Gamal AY, Mailhot JM. The effect of local delivery of PDGF-BB on attachment of human periodontal ligament fibroblasts to periodontitis-affected root surfaces in vitro. J Clin Periodontol 2000;27:347-53.
127. Lohmann CH, Schwartz Z, Niederauer GG, Carnes DL Jr, Dean DD, Boyan BD. Pretreatment with platelet derived growth factor-BB modulates the ability of costochondral resting zone chondrocytes incorporated into PLA/PGA scaffolds to form new cartilage in vivo. Biomaterials 2000;21:49-61.
128. Embil JM, Papp K, Sabbald G, Tousignant J, Smiell JM, Wong B, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen 2000;8:162-8.
129. Deuel TF. Principles of Tissue Engineering. In: Lanza R, Langer R, Chick W, editors. San Diego: Academic Press: Austin R.G. Landes; 1997. p.133-4.
130. Piazuelo E, Jimenez P, Lanas A, Garcia A, Esteva F, Sainz R. Platelet-derived growth factor and epidermal growth factor play a major role in human colonic fibroblast repair activities. Eur Srug Res 2000;32:191-6.
131. Desfaits AC, Raymond J, Muizelaar JP. Growth factors stimulate neointimal cells in vitro and increase the thickness of the neointima formed at the neck of porcine aneurysms treated by embolization. Stroke 2000;31:498-507.
132. Aoyagi M, Yamamoto S, Azuma H, Yamamoto M, Tamaki M, Miimi Y, et al. Localization and effects of hepatocyte growth factor on smooth muscle cells during neointimal formaiton after balloon denudation. Histochem Cell Biol 1999;111:419-28.
133. Khouri RK, Hong SP, Deune EG. De novo generation of permanent neovascularized soft tissue appendages by platelet-derived growth factor. J Clin Invest 1994;494: 1757-63.
134. Khouri RK, Koudsi B, Deune EG, Hong SP, Ozbek MR, Serdar CM, et al. Tissue generation with growth factors. Surgery 1993;114:374-9.
135. Lee YM, Park YJ, Lee SJ, Ku Y, Han SB, Klokkevold PR, et al. The bone regenerative effect of platelet-derived growth factor-BB delivered with a chitosan/tricalcium phosphate sponge carrier. J Periodontol 2000;71:418-24.
136. Kim HD, Valentini RF. Human osteoblast response in vitro to platelet-derived growth factor and transforming growth factor-beta delivered from controlled-release polymer rods. Biomaterials 1997;18:1175-84.
137. Walsh WR, Kim HD, Jong YS, Valentini RF. Controlled release of platelet-derived growth factor using ethylene vinyl acetate copolymer (EVAc) coated on stainless-steel wires. Biomaterials 1995;16:1319-25.
138. Park YJ, Ku Y, Chung CP, Lee SJ. Controlled release of platelet-derived growth factor from porous poly (L-lactide) membranes for guided tissue regeneration. J Control Release 1998;51:201-11.
139. Langer R, Vacanti JP. Tissue engineering. Science 1993; 260:920-6.
140. Massague J. The transforming growth factor- family. Annu Rev Cell Biol 1990;6:597-641.
141. Roberts AB, Sporn MB. The transforming growth factor-βs. Handbook Exp Pharmacol 1990;95:419-72.
142. Attisano L, Wrana JL, Massague J. TGF- β receptors and actions. Biochim Biophys Acta 1994;1222:71-80.
143. Lind M. Growth factors, possible new clinical tools: a review. Acta Orthop Scand 1996;67:407-17.
144. Roberts AB, Sporn MB. Physiological action and clinical applications of transforming growth factor- β. Growth Factors 1993;8:1-9.
145. Wakefield LM, Winoker TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent TGF- β1 and a different tissue distribution. J Clin Invest 1991;86:1976-84.
146. Trippel SB, Coutts RD, Einhorn TA, Mundy GR, Rosenfeld RG. Growth factors as therapeutic agents. J Bone Joint Surg Am 1996;78:1272-86.
147. Miyazono K, Heldin CH. Role of carbohydrate structure in TGF- β latency. Nature 1989;338:158-60.
148. Schulz-Cherry S, Ribeiro S, Gentry L, Murphy UJ. Thrombospondin binds and activates the small and large forms of latent transforming growth factor- β in a chemically defined system. J Biol Chem 1994;269:26775-82.
149. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH. Transforming growth factor -beta1, -beta2, and -beta3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992;267: 19482-8.
150. Pelton RW, Johnson MD, Perkett EA, Gold LI, Moses HL. Expression of transforming growth factor -betal, -beta2 and -beta3 mRNA and protein in the murine lung. Am J Respir Cell Mol Biol 1991;5:522-30.
151. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor- β1 is a heparin-binding region and isolation of heparins with varying affinity for TGF- β1. J Cell Physiol 1992;152:430-40.
152. Keski-Oja, Lohi K, Laiho M. Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin Thromb Hemost 1991;17:231-9.
153. Sporn MB, Roberts AB. A major advance in the use of growth factors to enhance wound healing. J Clin Invest 1993;92:2565-6.
154. Einhorn T. Enhancement of fracture-healing. J Bone Joint Surg Am 1995;77:940-56.
155. Pandit A, Ashar R, Feldman D. The effect of TGF-beta delivered through a collagen scaffold on wound healing. J Invest Surg 1999;12:89-100.
156. Schultz G, Rotatori DS, Clark W. EGF and TGF-alpha in wound healing and repair. J Cell Biochem 1991; 45:346-52.
157. Terrel TG, Working PK, Chow CP, Green JD. Pathology of recombinant human transforming growth factor-β1 in rats and rabbits. Int Rev Exp Pathol 1993;34: 43-67.
158. Bonewald LF, Mundy GR. Role of transforming growth factor-beta remodeling. Clin Orthop 1990;250:261-76.
159. Centrella M, Massague J, Canalis E. Human platelet-derived transforming growth factor β stimulates parameters of bone growth in fetal rat calvaria. Endocrinology 1986;119:2306-12.
160. Noda M, Camilliere JJ. In vivo stimulation of bone formation by transforming growth factor- β. Endocrinology 1989;124:2991-4.
161. Beck LS, Deguzman L, Lee WP, Xu Y, McFatridge LA, Gillett NA, et al. TGF- β1 induces bone closure of skull defects. J Bone Miner Res 1991;6:1257-65.
162. Gombotz WR, Pankey SC, Bouchatd LS, Ranchalis J, Puolakkainen P. Controlled release of TGF- β1 from a biodegradable matrix for bone regeneration. J Biomater Sci Polym Edn 1993;5:49-63.
163. Beck LS, Amento EP, Xu Y, Deguzman L, Lee WP, Nguyen T, et al. TGF- β1 induces bone closure of skull defects: temporal dynamics of bone formation in defects exposed to rhTGF-betal. J Bone Miner Res 1993;8: 753-61.
164. Bolander ME. Regulation of fracture repair by growth factors. Proc Soc Exp Biol Med 1992;200:165-70.
165. Tanaka T, Taniguchi Y, Gotoh K, Satoh R, Inazu M, Ozara H. Morphological study of recombinant human transforming growth factor betal-induced intramembranous ossification in neonatal rat parietal bone. Bone 1993;14:117-23.
166. Moxham JP, Kibblewhite DJ, Bruce AG, Rigley T, Gillespy T 3rd, Lane J. Transforming growth factor-betal in a guanidine-extracted demineralized bone matrix carrier rapidly closes a rabbit critical calvarial defect. J Otolaryngol 1996;25:82-7.
167. Sumner D, Turner T, Purchio A, Gombotz W, Urban R, Galante J. Enhancement of bone ingrowth by transforming growth factor-beta. J Bone Joint Surg Am 1995;77:1135-47.
168. Lind M, Overgaard S, Ongpipattanakul B, Nguyen T, Bunger C, Soballe K. Transforming growth factor-betal stimulates bone ongrowth to weight-loaded tricalcium phosphate collated implants: and experimental study in dogs. J Bone Joint Surg Br 1996;78:377-82.
169. Peter SJ, Lu L, Kim DJ, Stamatas GN, Miller MJ, Yaszemski MJ, et al. Effects of transforming growth factor beta1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly (prolylene fumarate) substrates. J Biomed Mater Res 2000;50:452-62.